A Systematic Review on Re-irradiation with Charged Particle Beam Therapy in the Management of Locally Recurrent Skull Base and Head and Neck Tumors

Mauricio E. Gamez M.D.1; Samir H. Patel M.D.2; Lisa A. McGee M.D.2; Terence T. Sio M.D.2; Mark McDonald M.D.3; Jack Phan M.D.4; Daniel J. Ma M.D.5; Robert L. Foote M.D.5; Jean-Claude M. Rwigema M.D.2

1Radiation Oncology, The Ohio State University – The James Cancer Center, Columbus, OH, USA
2Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA
3Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
4Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
5Radiation Oncology, Mayo Clinic, Rochester, MN, USA

Abstract

Purpose: To evaluate the clinical outcomes and treatment related toxicities of charged particle-based re-irradiation (reRT; protons and carbon ions) for the definitive management of recurrent or second primary skull base and head and neck tumors.

Materials and Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied for the conduct of this systematic review. Published work in English language evaluating the role of definitive charged particle therapies in the clinical setting of reRT for recurrent or second primary skull base and head and neck tumors were eligible for this analysis.

Results: A total of 26 original studies (15 protons, 10 carbon ions, and 1 helium/neon studies) involving a total of 1,118 patients (437 with protons, 670 with carbon ions, and 11 with helium/neon) treated with curative-intent charged particle reRT were included in this systematic review. All studies were retrospective in nature, and the majority of them (n=23, 88%) were reported as single institution experiences (87% for protons, and 90% for carbon ion-based studies). The median proton therapy reRT dose was 64.5 Gy (RBE 1.1) (range, 50.0 – 75.6 Gy), while the median carbon ion reRT dose was 53.8 Gy (RBE 2.5 – 3.0) (range, 44.8 – 60 Gy). Induction and/or concurrent chemotherapy was administered to 232 (53%) of the patients that received a course of proton reRT, and 122 (18%) for carbon ion reRT patients. ReRT with protons achieved 2-year local control rates ranging from 50% to 86%, and 41% to 92% for carbon ion reRT. The 2-year overall survival rates for proton and carbon ion reRT ranged from 33% to 80%, and 50% to 86% respectively. Late G3 toxicities ranged from 0% to 37%, with brain necrosis, ototoxicity, visual deficits, and bleeding as the most common complications. Grade 5 toxicities for all treated patients occurred in 1.4% (n=16/1118) with fatal bleeding as the leading cause.

Conclusions: Based on current data, curative intent skull base and head and neck reRT with charged particle radiotherapy is feasible and safe in well-selected cases, associated with comparable or potentially improved local control and toxicity rates compared to historical reRT studies using photon radiotherapy. Prospective multi-institutional studies are needed to validate these findings and to identify optimal patient selection criteria.
reporting oncologic outcomes, toxicity, and dosimetric treatment planning data are warranted to further validate these findings and to improve the understanding of the clinical benefits of charged particle radiotherapy in the reRT setting.

Keywords: proton therapy, carbon ion therapy, particle beam therapy, charged particle therapy, re-irradiation, skull base and head and neck cancer.

Introduction

Head and neck cancers pose a global clinical challenge, with an annual incidence of more than 650,000 cases and 330,000 deaths [1]. The majority of patients present with squamous cell carcinomas of the nasopharynx, oropharynx, oral cavity, hypopharynx, or larynx, although many other histologies and tumor subsites are clinically recognized. The variably aggressive and diverse anatomic and biological behaviors contribute to the complexity of disease management and difficulty in achieving optimal treatment outcome. Consequently, even after curative intent therapy, recurrence is quite common despite advances in multimodality management of head and neck cancers [2, 3].

Salvage surgery is considered the first-line therapy, for the majority of previously irradiated recurrent cases, with the exception of recurrent nasopharyngeal cancer were re-irradiation (reRT) remains the first choice of treatment. However, not all patients are candidates for salvage surgery as they may be medically unfit for surgery, salvage surgery may be unreasonably morbid or unable to achieve a complete resection, or patients may decline surgery [4, 5]. Given limited salvage options, reRT has historically played a role in the management of recurrent head and neck cancer, but posed quite a challenge due to lower chances of disease control coupled with the increased risk for severe toxicities [6]. ReRT with modern techniques such as intensity modulated (IMRT) and stereotactic body radiotherapies (SBRT) has led to improved tumor control with less severe toxicity and improved quality of life when compared to re-RT with 2D and 3D conformal radiotherapies [7, 8].

Charged particle radiotherapy including proton (PT) and carbon ion radiotherapy (CT) are frequently considered for reRT due to their more favorable radiation dosimetry, which can often improve normal tissue sparing of organs at risk from additional radiation. In previously irradiated patients, the therapeutic window is often narrow, and there may be significant risks associated with the high cumulative radiation dose to normal tissues, which can be mitigated through improved sparing of these normal non-target tissues. More data on the efficacy and comparative effectiveness of charged particle therapy in the setting of re-irradiation are needed to better understand the most appropriate application of this limited resource and to guide further clinical investigation. This review evaluates the clinical outcomes and treatment related toxicities of charged particle reRT for the definitive management of recurrent or second primary skull base and head and neck neoplasms.

Materials and Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied for the conduct of this systematic review [9]. Published work in English language evaluating the role of charged particle reRT in the setting of recurrent or second primary head and neck neoplasms that have previously undergone at least one prior course of RT, and with charged particle reRT delivered overlapping with the prior irradiated field were eligible for this analysis.

A broad search was initially performed, and included the following databases: PubMed, Medline, Embase, Cochrane, Google Scholar, Ovid, Scopus, as well as publications identified from references of previously published articles, and articles known to the authors. The initial search sought to comprehensively identify all published articles addressing the topic by using the following legends: (Proton(s), Proton Radiation Therapy, Proton Therapy, Proton Beam Therapy, Proton Beam, Charged Particle, Charged Particle Therapy, Particle Therapy, and Carbon ion (s)), (Reirradiation, Re-irradiation, Reradiation, Re-radiation, Radiation Retreatment, Radiation Re-treatment, Retreat, Re-treat, reRT, and re-RT), (Recurrent Cancer, Recurrent Disease, Secondary Cancer, Secondary Malignancy, Salvage Treatment), and (head and Neck, Head and Neck Disease Site). Disease site-specific searching criteria included: Pharynx, Nasopharynx, Oropharynx, Larynx, Hypopharynx, Oral Cavity, Oral Cancer, Salivary Gland, Parotid, Parotid Gland, Skin Cancer, Scalp, Sinonasal, Sino-nasal, Paranasal Sinuses, Para-Nasal Sinuses, Sinuses, Nasal, Nasal Cavity, Base of Skull, Skull Base, Scalp, Orbit, Eye, Ocular, Thyroid, and Thyroid Gland.

No date restrictions were employed in our planned search. All identified published articles through July 2020 were included in the initial evaluation. All articles were screened by 2 authors: Mauricio E. Gamez, and Jean-Claude Rwigema. A total of 141 studies were identified based on our initial search criteria: 137 from the database(s) search, and 4 additional articles were
identified through other sources (Fig. 1). Publications of the same study population from the same institution or group of investigators and/or series that used charged particle reRT as a palliative treatment option were excluded. After these reports were removed, the remaining 106 eligible items were screened based on the previously discussed search criteria, and a total of 56 records were further excluded. In addition, articles without any well specified clinical endpoints (ie. local control, survival, or side effects) of charged particle radiotherapy were also excluded. Of the 50 remaining publications, review articles, abstracts, letters to the editor, commentaries, and studies with ≤ 5 reRT patients were excluded. Thus, 26 original studies were found to have sufficient focus and relevance to be incorporated and analyzed in this systematic review. A meta-analysis was not performed due to the heterogeneity of the reported reRT head and neck series, and the lack of consistent statistical power and value in this setting.

Results
A total of 26 original published studies (15 protons, 10 carbon ions, and 1 helium/neon ion particle radiotherapy) involving a total of 1118 patients (437 with protons, 670 with carbon ions, and 11 patients with helium/neon ions) who were treated with curative-intent charged particle reRT were included in this comprehensive systematic review [10 – 35]. According to head and neck subsite, charged particle reRT with either protons or carbon ions was most commonly used for recurrent sinonasal, nasopharyngeal and salivary gland tumors, with squamous cell and adenoid cystic cell carcinoma as the most frequent histologies. Table 1 and 2 summarizes the different reRT studies using either proton, carbon ion or helium/neon ion therapy for
Table 1. Series of proton reirradiation (reRT) of the head and neck (HN) and skull base series.

| Author [citation] | Study period | Study type | No. pts | Primary site histology (%) | Previous RT technique (%) | median previous RT dose (range)/fractionation |
|-------------------|--------------|------------|---------|-----------------------------|--------------------------|---------------------------------------------|
| Dionisi et al. [10] | 2015–2018 | Retrospective, single institution | 17 | NPC (35%), SCC (35%), Non-keratinizing carcinoma (23%), Undifferentiated carcinoma (42%) | 3D-CRT (35%), IMRT (65%) | 70 Gy (60–74)/2Gy (1.8–2.5) |
| Hayashi et al. [11] | 2009–2014 | Retrospective, single institution | 34 | Oral Cavity SCC (88%), ACC (6%), Mucocoeplorloid (3%), Ameloblastic Ca (3%) | EBRT (79%), BT (15%), PBT (59%) | 55 Gy (40–80)/NA |
| McDonald et al. [12] | 2004–2014 | Retrospective, single institution | 61 | Multiple HN disease sites SCC n = 32, Non-SCC n = 29 | EBRT (n = 61), IORT (n = 2), Gamma Knife (n = 3) | 64.6 Gy (43.2–74): SCC, 66 Gy (40–75.6): Non-SCC |
| Linton et al. [13] | 2004–2012 | Retrospective, single institution | 6/26 (23%) | Sinonasal, Nasopharynx, orbit, major/minor salivary glands—not specified for re-irradiated cases ACC (100%) | EBRT, SRS Gamma Knife NR | NA |
| Yu et al. [14] | 2010–2016 | Retrospective, multi-institution | 27/69 (39%) | Sinonasal SCC (41%), ACC (22%), Esthesio (15%), Adeno (15%), Other (7%) | NR NR | NA |
| Fan et al. [15] | 2013–2018 | Retrospective, single institution | 18/86 (21%) | Sinonasal, nasal cavity/ethmoid sinus (39%), other sinuses (61%), SCC (44%), ACC (17%), Esthesio (11%), Other (22%) | NR | 60 Gy (27–70) |
| Author [citation] | study period | institution [country] | Recurrent site salvage surgery before reRT (%) | reRT technique (%) | Median reRT dose (range)/fractionation | Median GTV (range) | GTV–CTV margin | CTV–PTV margin | OAR doses Gy (range) | reRT for HN tumors with charged particle beam therapy |
|------------------|--------------|-----------------------|-----------------------------------------------|-------------------|------------------------------------------|-------------------|--------------|---------------|------------------|--------------------------------------------------|
| Dionisi et al. [10] | 2015–2018     | Proton Therapy Unit, APSS (Italy) | Skull base (94%) | Nodal (6%) | PBT active scanning | 15.4 cm³ (5–43.3) | 0.5–1.5 cm | 3 mm (MFO), 4 mm (SFO) | Max cumulative carotid artery: 118.5 (109–129) | Max cumulative optic nerve: 47 (4–60) |
|                  |              |                       | 0 % | | SFO (76.5%) | Max optic nerve PBT: 16.5 (0.3–49) | | | | Max cumulative temporal lobe: 80.8 (30.5–117) |
|                  |              |                       | 30 (11–108) | | MFO (23.5%) | Mean inner ear PBT: 20 (3.7–61.5) | | | | Mean cumulative inner ear: 61.9 (33.7–98.6) |
|                  |              |                       | 1 (1–2) | | 60 Gy (30.6–66)/2 Gy (1.8–2) | | | | | |
|                  |              |                       |                      | | Curative, n = 16 (94%) | | | | | |
| Hayashi et al. [11] | 2009–2014 | Southern Tohoku Proton Therapy Center (Japan) | Tongue (38%) | Upper gingiva (26%) | PBT | NA | 3 mm | 3 mm, did not extend into critical OAR | |
|                  |              |                       | Lower gingiva (15%) | Buccal mucosa (9%) | | | | | Not performed |
|                  |              |                       | FOM (6%) | Hard palate (6%) | 50 Gy (28.6–55)/2.2 Gy | | | | |
| McDonald et al. [12] | 2004–2014 | Indiana University (United States) | Multiple HN disease sites | 11 (34%): SCC | PBT, uniform scanning | 72 Gy (66–75.6)/1.8–2 Gy | | | | |
|                  |              |                       | 18 (62%): Non-SCC | | | Curative, n = 34 (100%) | | | | Not performed |
|                  |              |                       | 17.5: SCC | 32: Non-SCC | 70 Gy (36–74.5): SCC | | | | |
|                  |              |                       | 1 course (81.3%): SCC | | 70.2 Gy (54–75.6): Non-SCC | | | | |
|                  |              |                       | 1 course (82.8%): Non-SCC | | Curative, n = 61 (100%) | | | | |
| Linton et al. [13] | 2004–2012 | Indiana University (United States) | Skull base | NR | PBT, uniform scanning | 72 Gy (66–75.6) | | | | |
|                  |              |                       | NR | | 1.8–2 Gy | | | | Allowed at preference of treating physician |
|                  |              |                       | NR | | Curative, n = 26 (100%) | | | | |
| Yu et al. [14] | 2010–2016 | (multi-institution)* PCG (United States) | Nasal cavity (52%) | Maxillary sinus (18%) | PBT, uniform scanning | NR | | | | |
|                  |              |                       | Ethmoid sinus (11%) | Sphenoid sinus (4%) | or pencil-beam scanning | | | | |
|                  |              |                       | Not specified (15%) | 13 (48%) | 60 Gy (18.2–72.3)/2 Gy | | | | Nodal irradiation (6%) |
|                  |              |                       |                           | | Curative, n = 27 (100%) | | | | |
| Fan et al. [15] | 2013–2018 | ProCure (United States) | Sinonasal, nasal cavity/ethmoid sinus (39%), other sinuses (61%) | 8 (44%) | PBT, 3D-CRT (55%), IMPT (45%) | NR | | | | |
|                  |              |                       |                           | 68 (54–76) | Curative (100%) | | | | |

Table 1. Extended.
| Author [citation]   | study period | institution [country] | Additional systemic therapies, (%) | Median age, y | Median F/u (mo) | Clinical outcomes, % | vPBT acute toxicities, G (%) | PBT late toxicities, G (%) |
|---------------------|-------------|-----------------------|-----------------------------------|--------------|----------------|----------------------|-----------------------------|-----------------------------|
| Dionisi et al. [10] | 2015–2018   | Proton Therapy Unit, APSS (Italy) | Induction chemotherapy (6%) Induction + concomitant (6%) Concomitant (CDDP) (18%) Concomitant (Carbo) (23%) No chemotherapy (47%) | 58           | 10             | Overall            | 1.5-y OS: 54%        | 23.5% G3 events             | Hearing impairment (18%) |
|                     |             |                       |                                   |              |                | 1.5-y LC: 67%       | After exclusion          | NO G3 events                | Fatal bleeding uncertain  |
|                     |             |                       |                                   |              |                | palliative case     | 1.5-y OS: 59%         | (6%)                        | cause                       |
|                     |             |                       |                                   |              |                | 1.5-y LC: 73%       |                                                                             |                             |
| Hayashi et al. [11] | 2009–2014   | Southern Tohoku Proton Therapy Center (Japan) | Weekly intra-arterial chemotherapy Median total dose of CDDP 300 mg (120–560) If residual primary tumor after 5-7 courses of intra-arterial CDDP, additional intra-arterial DOC was delivered Median total dose of DOC 48.5 (24–105) | 68           | 25             | 1-y OS: 62%       | 2-y OS: 42%           | G3 dysphagia (35%)         | G3 oral mucositis (32%) |
|                     |             |                       |                                   |              |                | 2-y LC: 77%        | 2-y LC: 60%           | G3 radiation dermatitis (29%) | G3 ORN (3%)                 |
|                     |             |                       |                                   |              |                | 22 pts (65%): CR  | 12 pts (35%): PR     | G3 dysphagia (3%)         | G3 oral mucositis (32%) |
| McDonald et al. [12]| 2004–2014   | Indiana University (United States) | Induction chemotherapy (3%): SCC Induction chemotherapy (3%): Non-SCC Concomitant chemotherapy (50%): SCC Concomitant chemotherapy (7%): Non-SCC | 62.5 SCC     | 15.2           | 2-y OS: 32.7%     | 2-y LF: 19.7%          | G5 CNS (n = 1)              | G3 dermatitis (n = 3) |
|                     |             |                       |                                   |              |                | 2-y LF: 33.3%     | 2-y DM: 38.3%          | G3 soft tissue/bone necrosis (n = 3) | G3 dermatitis (n = 3) |
|                     |             |                       |                                   |              |                |                   |                       | G3 mucositis (n = 2)     | G3 soft tissue/bone necrosis (n = 1) |
|                     |             |                       |                                   |              |                |                   |                       | G5 CNS (n = 1)           | G3–4 CNS (n = 3) |
|                     |             |                       |                                   |              |                |                   |                       | G5 soft tissue/bone necrosis (n = 1) | G3–4 CNS (n = 3) |
| Linton et al. [13]  | 2004–2012   | Indiana University (United States) | No concurrent systemic therapy | 46           | 24             | 2-y LC: 86%       | 2-y OS: 57%           | G3 ototoxicity (n = 1)   | G5 CNS fluid leak/meningitis (n = 1) |
|                     |             |                       |                                   |              |                | 2-y DM: 25%       |                       |                             |                             |
| Yu et al. [14]      | 2010–2016   | (multi-institution*) PCG (United States) | Concomitant chemotherapy (37%) | 58           | 26             | 3-y OS: 76%       | 3-y FFDM: 47%         | G3 mucositis (12%)       | G3 pain (6%)               |
|                     |             |                       |                                   |              |                | 3-y FFPD: 32%     | 3-y FFIR: 34%         | G3 dermatitis (4%)       | G3 skin irritation (4%)    |
|                     |             |                       |                                   |              |                | 3-y FFIR: 34%     |                       | G3 xerostomia (3%)        | G3 dysphagia (3%) |
|                     |             |                       |                                   |              |                |                   |                       | G3 anorexia (3%)          | G3 anorexia (3%) |
|                     |             |                       |                                   |              |                |                   |                       | G3 conjunctivitis (1%)    | G3 hearing impairment (1%) |
|                     |             |                       |                                   |              |                |                   |                       | G3 nausea (1%)            | G3 nausea (1%) |
|                     |             |                       |                                   |              |                |                   |                       | No ≥ G3 late toxicities   | G3 nausea (1%) |
|                     |             |                       |                                   |              |                |                   |                       | occurred                  |                             |
| Fan et al. [15]     | 2013–2018   | ProCure (United States) | Concomitant chemotherapy (n = 9, 50%), with CDDP (n = 6, 67%), cetuximab (n = 2, 22%), other (n = 1, 11%) | < 70 (72%)   | 23.4           | 2-y LC: 77%       | 2-y DFS: 54%          | G3 dermatitis (11%)      | G3 dysphagia/PEG (6%) |
|                     |             |                       |                                   | ≥ 70 (28%)   |                | 2-y OS: 66%       | 2-y DC: 80%           | G3 mucositis (6%)        | G3 mucoitis (6%)           |
|                     |             |                       |                                   |              |                |                   |                       | G3 brain necrosis (6%)    | G3 facial pain (6%)       |
|                     |             |                       |                                   |              |                |                   |                       | No G4 or 5 toxicities related to RT |                             |

**Table 1.** Extended.
### Table 1. Continued.

| Author [citation] | Study period | Institution [country] | Study type | No. pts | Primary site histology (%) | Previous RT technique (%) | median previous RT dose (range)/fractionation |
|-------------------|--------------|------------------------|------------|---------|----------------------------|----------------------------|-----------------------------------------------|
| Ng et al. [16]    | 2000–2016    | MDACC (United States)  | Retrospective, single institution | 15/75 (20%) | Skull base/orbit/sinonasal (53%), nasopharynx (13%), oral cavity (13%), oropharynx (7%), other (13%) | SCC (27%), Non-SCC (73%) | NR 60 Gy (30–74)/2 Gy |
| Romesser et al. [17] | 2011–2014    | (multi-institution) (United States) | Retrospective, multi-institution | 92 | Oropharynx (18%), oral cavity (13%), nasal cavity/paranasal sinuses (13%), salivary glands (12%), larynx/hypopharynx (11%), nasopharynx (10%), other (23%) | EBRT (100%) | 66 Gy (58.2–70): SCC 58.9 Gy (49.8–65.1): Non-SCC |
| Phan et al. [18]  | 2011–2015    | MDACC (United States)  | Retrospective, single institution | 60 | Oropharynx (25%), oral cavity (5%), nasopharynx (13%), larynx (2%), parotid (12%), orbit (5%), sinonasal (20%), neck/unknown primary (5%), other (13%) | SCC (67%), Non-SCC (33%) | NR 60 Gy (45–72): SCC 60 Gy (30–70): Non-SCC |
| Azami et al. [19] | 2009–2012    | Southern Tohoku Proton Therapy Center (Japan) | Retrospective, single institution | 6/10 (60%) | Parotid gland ACC (40%), EMC (20%), Sarcoma (10%), SCC (10%), MC (10%), Acinic cell (10%) | NR | 57.5 Gy |
| Yang et al. [20]  | 2014–2018    | Shanghai Proton and Heavy Ion Center (China) | Retrospective, single institution | 12/51 (23%) | Multiple HN sites Sarcoma (100%) | NR | NR |
### Table 1. Continued. Extended.

| Author [citation] | study period | institution [country] | Recurrent site salvage surgery before reRT (%) | median time to reRT (mo) | median No. previous RT treatments (range) | reRT technique | median reRT dose (range)/fractionation | Median GTV (range) | GTV–CTV margin | CTV–PTV margin | OAR doses Gy (range) | nodal irradiation |
|-------------------|--------------|-----------------------|-----------------------------------------------|-------------------------|------------------------------------------|----------------|--------------------------------------|-----------------|----------------|----------------|----------------------|------------------|
| Ng et al. [16]    | 2000–2016    | MDACC (United States) | Skull Base (100%)                              | 9 (60%)                 | NR                                       | PBT            | 66 Gy (50–70)/2 Gy Curative (100%)   | 24 cm³ (9.4–45.6) | NR             | NR             | Not performed       |                  |
| Romesser et al. [17] | 2011–2014    | (multi-institution²) (United States) | Oropharynx (15%), nasal cavity/paranasal sinuses (14%), oral cavity (17%), salivary glands (13%), nasopharynx (13%), larynx/hypopharynx (10%), other (17%) | 36 (39%) | 34 | 1 course (83%) | 2 courses (14%) | ≥ 3 courses (3%) | PBT, uniform scanning | 66 Gy (53.1–66.2): SCC | 60.1 Gy (50–66): Non-SCC | Curative (100%) | CTV volume | 90.8 cm³ (33.4–188.3): SCC | 69.1 cm³ (69.1–26.8–138.1): Non-SCC | CTV–PTV margin: 3 mm | NR | NR |
| Phan et al. [18]  | 2011–2015    | MDACC (United States) | Oropharynx (27%), oral cavity (2%), nasopharynx (8%), larynx (3%), parotid (13%), orbit (13%), sinonasal (18%), skull base (7%), neck (10%) | 22 (55%): SCC | 13 (65%): Non-SCC | 47.6: SCC | 33.5: Non-SCC | PBT, passive scatter | 66 Gy (50–70): Passive scatter | 66 Gy (55–70): IMPT | Curative (100%) | 7.1 cm³ (2.4–45.6): passive scatter | 11.2 cm³ (1.0–138.1): IMPT | CTV–PTV margin: 3 mm | Max right optic nerve 17.5 (1.9–53.9): passive scatter | Max right optic nerve 10.5 (1.8–51.7): IMPT | Max left optic nerve 9.1 (0.6–72.5): passive scatter | Max left optic nerve 3.2 (3.7–50.4): IMPT | Max optic chiasm 6.4 (0.5–49.4): passive scatter | Max optic chiasm 14.0 (0.7–53.2): IMPT | Max brainstem 6.5 (0.5–52.9): passive scatter | Max brainstem 14.1 (0.5–45.70: IMPT | Max spinal cord 5.3 (0.4–21.1): passive scatter | Max spinal cord 11.2 (0.4–42.9): IMPT | Mean cochlea 12.2 (0.3–51.8): IMPT | Mean cochlea 15.1 (0.3–51.8): IMPT | Mean parotid 11.5 (0.4–45.7): passive scatter | Mean parotid 8.7 (0.3–49.5): IMPT | Mean oral cavity 3.8 (1.4–6.2): passive scatter | Mean oral cavity 8.1 (0.5–56.6): IMPT | Allowed based on particular case and at preference of treating physician |
| Azami et al. [19] | 2009–2012    | Southern Tohoku Proton Therapy Center (Japan) | Parotid gland (100%) | 0% | NR | NR | PBT | 66 Gy (56–77)/2-2.2 Gy Curative (100%) | NR | GTV–CTV margin: 3–5 mm | CTV–PTV margin: 3–5 mm, did not extend to critical OAR | NR | Not performed |
| Yang et al. [20]  | 2014–2018    | Shanghai Proton and Heavy Ion Center (China) | Multiple HN sites, not specified | NR for proton patients | NR | NR | PBT (IMPT) and/or IMCT, not specified for reRT cases | NR | GTV–CTV margin: 1–3 mm | NR | NR |
### Table 1. Continued. Extended.

| Author [citation] | study period institution [country] | Additional systemic therapies, (%) | Median age, y | Median F/u (mo) | Clinical outcomes, % | vPBT acute toxicities, G (%) | PBT late toxicities, G (%) |
|-------------------|-----------------------------------|----------------------------------|--------------|----------------|-----------------------|-----------------------------|-----------------------------|
| Ng et al. [16]    | 2000–2016 MDACC (United States)   | Induction chemotherapy (7%)      | 66           | 24             | 2-y LC: 59% 2-y RC: 78% 2-y DC: 93% 2-y PFS: 49% 2-y OS: 74% | G3 mucositis (13%)          | G3 dermatitis (7%) G3 ORN and dysphagia (7%) |
|                   |                                   | Concomitant chemotherapy (67%)   |              |                |                       |                             | G3 glaucoma (7%) G3 trismus (7%) G3 fibrosis (7%) |
| Romesser et al. [17] | 2011–2014 (multi-institution*) (United States) | Neoadjuvant chemotherapy (4%) Neoadjuvant and concurrent chemotherapy (9%) Concurrent chemotherapy (39%) Cetuximab most common regimen | 63           | 13             | 1-y LRC: 75% 1-y FFDM: 84% 1-y OS: 65% | G3 mucositis (10%)          | G3 dysphagia (9%) G3 esophagitis (9%) G3 dermatitis (3%) G3 skin (9%) G3 dysphagia (7%) G5 bleeding (3%) |
| Phan et al. [18]  | 2011–2015 MDACC (United States)   | Induction chemotherapy (8%)      | 66: SCC      | 13.6           | 1-y LRC: 81% 1-y LFFS: 68% 1-y OS: 81% 1-y PFS: 60% 1-y DMFS: 75% | G3 mucositis (13%)          | G3 dermatitis (13%) G3 dysphagia (10%) G3 odynophagia (10%) G3 dysphagia (5%) G3 xerostomia (3%) G3 pain (8%) G3 ototoxicity (10%) G3 dysphagia (2%) G3 xerostomia (2%) G3 neurotoxicity (3%) G3 tracheostomy (3%) G4 ORN (3%) G5/death (2%) |
|                   |                                   | Concurrent chemotherapy (73%)    | 60.5: Non-SCC|                |                       |                             |                             |
| Azami et al. [19] | 2009–2012 Southern Tohoku Proton Therapy Center (Japan) | Concurrent intra-arterial chemotherapy (CDDP) (50%) | 62           | 24             | 1-y OS: 80% 1-y LC: 80% 3-y OS: 60% 3-y LC: 60% | No G3 toxicities encountered |                             |
| Yang et al. [20]  | 2014–2018 Shanghai Proton and Heavy Ion Center (China) | Concurrent chemotherapy (n – 6, 50%) | 36           | 15.7           | 1-y OS: 67% | G4 bleeding (8%) G5 bleeding (8%) |                             |
Table 1. Continued.

| Author [citation] | Study period | Study type | Primary site histology (%) | Previous RT technique (%) | median previous RT dose (range)/fractionation |
|-------------------|--------------|------------|-----------------------------|---------------------------|---------------------------------------------|
| Dale et al. [21]  | 2012–2016    | Retrospective, single institution | Rhinopharynx (35%), oropharynx (18%), oral cavity (12%), brain/ meninges (18%), nasal cavity (6%), larynx (6%), skin scalp/face (6%) | EBRT (100%) | 66 Gy (32–70)/2Gy |
|                   | National Center of Oncological Hadrontherapy (CNA0) (Italy) | 17/96 (18%) | SCC (76%) | | |
|                   |              |            | Undifferentiated carcinoma (6%) | | |
|                   |              |            | High-grade glioma (12%) | | |
|                   |              |            | Meningioma (6%) | | |
| Marucci et al. [22] | 1984–2000 | Retrospective, single institution | Eye | PBT | 70 Gy/5 fractions (90% cases) |
|                   | Harvard Cyclotron Laboratory (United States) | 31 | Uveal melanoma (100%) | | |
| McDonald et al. [23] | 2005–2012 | Retrospective, single institution | Clivus (50%), cervical spine (12%), thoracolumbar spine (19%), sacrum (19%) | EBRT (37%) | 75.2 (40–79.2) |
|                   | Indiana University (United States) | 16 | Chordoma (100%) | | |
| Lin et al. [24] | 1991–1997 | Retrospective, single institution | Nasopharynx (100%) | Conventional RT (100%) ± brachytherapy implant (n = 4. 25%) | 71.8 (50–88.2) |
|                   | Loma Linda University Medical Center (United States) | 16 | NR | | |

Abbreviations: pts, patients; RT, radiotherapy; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning target volume; OAR, organs at risk; F/u, follow-up; PBT, proton beam therapy; G, grade; APSS, Azienda Provinciale per i Servizi Sanitari; NPC, nasopharyngeal carcinoma; SCC, squamous cell carcinoma; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; SFO, single-field optimization; MFO, multifield optimization; max, maximum; CDDP, cisplatin; carbo, carboplatin; OS, overall survival; LC, local control; ACC, adenoid cystic carcinoma; Ca, cancer; EBRT, external beam radiotherapy; BT, brachytherapy; NA, not available; FOM, figure of merit; NR, not reported; LN, lymph node; ENL, elective nodal irradiation; DOC, XXXX; CR, complete remission; PR, partial remission; ORN, osteonecrosis; IORT, intraoperative radiation therapy; LF, local failure; RF, regional failure; DM, distant metastasis; CNS, central nervous system; PCG, Proton Collaborative Group; esthesio, esthesioneuroblastoma; adeno, adenocarcinoma; FFDM, freedom from distant metastasis; FDGP, freedom from distant progression; FFLR, freedom from locoregional recurrence; 3DCPT, 3-dimensional conformal proton therapy; DFS, disease-free survival; DC, XXXX; PEG, percutaneous endoscopic gastrostomy; MDACC, MD Anderson Cancer Center; PFS, progression-free survival; LRC, locoregional control; LFPS, local failure-free survival; DMFS, distant metastasis-free survival; CB, contour beam; FFM, fat-free mass; trach, tracheostomy; CSF, cerebrospinal fluid; LRPFs, locoregional progression-free survival; EMC, epithelial myoepithelial carcinoma; MC, mucoepidermoid carcinoma; IMCT, intensity-modulated carbon therapy; Cum, cumulative; Dmax, maximum dose; Eq, equivalent; SRS, stereotactic radiosurgery; BS, branch site; BID, twice a day.

aMulti-institutions: Mayo Clinic, Northwestern Medicine Chicago Proton Center, ProCure Therapy Center, Seattle Cancer Care Alliance Proton Therapy Center, University of Maryland Proton Treatment Center, California Proton Cancer Therapy Center, Willis-Knighton Cancer Center.

bMulti-institutions: Memorial Sloan Kettering Cancer Center, ProCure Proton Therapy Center, Montefiore Medical Center, Northwestern Medicine Chicago Proton Center.
| Author [citation] | study period | institution [country] | Recurrent site salvage surgery before reRT (%) | reRT technique | Median GTV (range) | Median time to reRT (mo) | median No. previous RT treatments (range) | median reRT dose (range)/fractionation | Median reRT fractionation | treatment intent | Median GTV–CTV margin | CTV–PTV margin | OAR doses Gy (range) | nodal irradiation |
|------------------|-------------|----------------------|-----------------------------------------------|---------------|------------------|----------------------|-------------------------------------------|------------------------------------|----------------------------|-----------------|-------------------|------------------|----------------|------------------|---------------------|
| Dale et al. [21] | 2012–2016   | National Center of Oncological Hadrontherapy (CNA0) (Italy) | Not specified for the reRT proton patients | PBT | NR               | 16 (94%)             | 3.4 y                       | Not specified for the reRT proton patients | 54 Gy (30–70)/2 Gy                     | Curative (100%) | NR                | NR               | Median CumDmaxEqd2 carotid arteries: 109 (25–167) | NR                |
| Marucci et al. [22] | 1984–2000  | Harvard Cyclotron Laboratory (United States) | Eye | PBT | Tumor volume 0.44 cm³ | 0%                   | 36 (8–165)                  | All patients received a prior course of RT, except for one who received 2 prior courses | 70 Gy/5 fractions (97% cases)           | Curative (100%) | NA               | NR               | NA               | NA               |
| McDonald et al. [23] | 2005–2012  | Indiana University (United States) | Clivus (50%), cervical spine (12%), thoracolumbar spine (19%), sacrum (19%) | PBT | 71 cm³ (0–701) | 8 (50%)             | 37 (12–129)                  | 1 prior course (81%) 2 prior courses (12%) 4 prior courses (7%) | 75.6 (71.2–79.2)/1.8–2, except for 2 pts where tumor abutted the BS and were treated with hyperfractionated RT 1.2 Gy BID | Curative (100%) | NR               | NR               | Doses to OAR (BS, optic chiasm, optic nerves, spinal cord, brachial plexus) reported case by case | NR               |
| Lin et al. [24] | 1991–1997  | Loma Linda University Medical Center (United States) | Nasopharynx (100%) | Conformal PBT | NR               | 3 (19%)              | 34                            | 1 prior course (100%) | 62.8 (59.4–70.2)/1.8-2 | Curative (100%) | NR               | NR               | Mean max surface dose BS 11.4 Gy (1.8–20) Mean 90% of BS volume <6.88 Gy Mean 50% of BS volume 1.2 Gy Mean 10% of BS volume 2.2 Gy Mean max dose to optic chiasm 0.4 Gy (0–3.8) Mean 90% of optic chiasm volume <7.89 Gy Mean 50% of optic chiasm volume 1.0 Gy Mean 10% of optic chiasm volume 1.8 Gy Mean max dose optic nerves 7.1 Gy (0–22) Mean 90% of optic nerves volume 0 Mean 50% of optic nerves volume 1.4 Gy Mean 10% of optic nerves volume 3.7 Gy | NR               |
### Table 1. Continued. Extended.

| Author [citation] study period institution [country] | Additional systemic therapies, (%) | Median age, y | Median F/u (mo) | Clinical outcomes, % | vPBT acute toxicities, G (%) | PBT late toxicities, G (%) |
|-----------------------------------------------------|-----------------------------------|---------------|----------------|----------------------|----------------------------|----------------------------|
| Dale et al. [21] 2012–2016 National Center of Oncological Hadrontherapy (CNA0) (Italy) | Not specified | 55 | 13.4 | 1-y CB rate: 2.7% 1-y OS: 81.5% | G5 bleeding (12%), not specified if cause of death was due to CB or tumor progression | No other toxicities reported |
| Marucci et al. [22] 1984–2000 Harvard Cyclotron Laboratory (United States) | NR | 61 | 59 | 5-y OS: 63% 5-y LR: 31% 5-y FFM: 66% 5-y survival with eye retention: 40% | 9 eyes (29%) enucleated after reRT, 4 of them because of painful eye. Only 5/15 pts who had 20/200 vision before reRT maintained vision at that level |
| McDonald et al. [23] 2005–2012 Indiana University (United States) | NR | 59 | 23 | 2-y LC: 85% 2-y OS: 80% 2-y DM: 20% | G3 laryngeal edema (6%), required permanent trach G4 ventricular obstruction, required urgent shunt placement, G3 brain necrosis (6%) G4 ischemic BS stroke (6%) G4 CSF leak/meningitis (6%) 2-y estimated late grade 3 or 4 toxicity: 19% |
| Lin et al. [24] 1991–1997 Loma Linda University Medical Center (United States) | Chemotherapy and/or immunotherapy was administered in (81%), either in conjunction with conventional RT, following conventional RT, or following PBT | 46 (mean) | 23.7 (mean) | 2-y LRPFS: 50% 2-y OS: 50% 2-y LC: 50% 2-y DFS: 50% | Acute toxicities not graded G3–4 ORN (6%) G3–4 chronic ulceration nasopharynx (6%) G3 trismus (6%) G3–4 serious otitis (12%) No CNS complications observed |
## Table 2. Carbon ion reirradiation (reRT) head and neck (HN) and skull base series.

| Author [citation] | Study period | Study type | Institution (country) | Study type No. pts | Primary site histology (%) | Previous RT technique (%) | Median previous RT dose (range)/fractionation | Recurrent site salvage surgery before reRT (%) | Median time to reRT (mo) | Median No. previous RT treatments (range) |
|-------------------|--------------|------------|------------------------|-------------------|---------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------|------------------------------------------|
| Hu et al. [25]    | 2015–2017    | Retrospective, single institution | Shanghai Proton and Heavy Ion Center (China) | 75    | Nasopharynx poorly differentiated or undifferentiated SCC (100%) | IMRT (96%), non-IMRT (4%) | 70 Gy (66–75.75) | Nasopharynx | NR | 29 (11–216) |
| Jensen et al. [26] | 2009–2010 | Retrospective, single institution | Heidelberg Ion Therapy Centre (Germany) | 15/16 | Skull base (50%), Paranasal sinus (19%), Nasopharynx (12%), Posterior fossa (6%), EAC (6%), ACC (38%), Mucoepidermoid (6%), Acinic cell (6%), Chordoma (25%), Chondrosarcoma (12%), SCC (12%) | EBRT (56%), PBT (6%), CT (38%) | 67 Gy (38–72) | Skull base (50%), Paranasal sinus (19%), Nasopharynx (12%), Posterior fossa (6%), EAC (6%), Chordoma (25%), Chondrosarcoma (12%), SCC (12%) | 0% | 73 (12.2–349.6) | 1 |
| Yamazaki et al. [27] | 2000–2010 (multi-institution*) | Retrospective, multi-institution | (Japan) | 17/26 CT, 9/26 PBT | Nasopharynx (15%), oral cavity (8%), salivary gland (12%), sinonasal (58%), other (8%) | EBRT or PBT (% NR) ≥ 40 Gy | 70.2 Gy (61–81) | Nasopharynx (15%), oral cavity (8%), salivary gland (12%), sinonasal (58%), other (8%) | 9 (35%) | 13 (4–92) | NR |
| Feehan et al. [28] | 1981–1990 | Retrospective, single institution | Lawrence Berkeley Laboratory (United States) | 11 | Nasopharynx SCC (91%), Lymphoepithelioma (9%) | EBRT ± brachytherapy (100%) | 70.2 Gy (61–81) | Skull base (100%) plus neck (18%) | 0% | NR | NR |
| Held et al. [29]  | 2010–2017    | Retrospective, single institution | Heidelberg Ion Therapy Centre (Germany) | 229 | Salivary glands (24%), Nasopharynx (23%), Paranasal sinus (21%), Oral cavity (10%), Oropharynx (8%), Hypopharynx (2%), Other (14%), ACC (54%), SCC (26%), Adeno (8%), Other (11%) | IMRT (35%), 3D-conformal (23%), IMRT + CT boost (28%), Other (6%), Unknown (8%) | 67.4 Gy (36.5–84) | Salivary glands (24%), Nasopharynx (23%), Paranasal sinus (21%), Oral cavity (10%), Oropharynx (6%), Hypopharynx (6%), Other (14%), 39 (17%), 3.9 y | 1 prior course (93%) | 2 prior courses (7%) |
| Hayashi et al. [30] | 2007–2016 | Retrospective, single institution | Hospital National Institute of Radiological Sciences (Japan) | 48 | Nasal (37%), paranasal (31%), lacrimal gland/orbit (8%), nasopharynx (6%), palate (4%), SMG (2%), tongue (2%), bone of skull or cervical vertebra (8%), other (4%) | NR | 57.6 Gy (48–70.4)/12–16 fractions | Paranasal (37%), nasal (19%), nasopharynx (8%), orbit (6%), cavernous sinus (6%), bone of skull or cervical vertebra (12%), other (10%) | 0 % | 24.2 (4.5–112.5) | 1 prior course (85%) | 2 prior courses (15%) |
| Author [citation] | reRT technique (%) | Median GTV (range) | GTV–CTV margin | CTV–PTV margin | OAR doses Gy (range) | Additional systemic therapies (%) |
|------------------|--------------------|-------------------|---------------|----------------|---------------------|----------------------------------|
| Hu et al. [25]   | IMCT               | NR                | NR            | NR             | NR                  | Induction chemotherapy (61%)     |
| 2015–2017        | 57.5 (50–66)/3      |                     |               |                |                     | TP (25%)                         |
| Shanghai Proton  |                    |                   |               |                |                     | GP (23%)                         |
| and Heavy Ion    | curative (100%)    |                   |               |                |                     | Others (13%)                     |
| Center (China)   |                    |                   |               |                |                     | Concurrent chemotherapy (16%)    |
|                  |                    |                   |               |                |                     | Weekly CDDP (11%)                |
|                  |                    |                   |               |                |                     | High-dose CDDP (5%)              |
| Jensen et al. [26] | CT alone (87%), IMRT + CT boost (6%), IMRT + PBT boost (6%) | PTV volume 61.1 cm³ (9.2–284.1) | CTV–PTV margin: 3 mm, did not extend into critical OAR | Max cumulative dose to spinal cord <8.6Gy | Max cumulative dose to BS <8.6Gy | Induction chemotherapy (6%) |
| 2009–2010        | 44.8 Gy (36–72.7)  | curative (100%)   |               |                |                     |                                  |
| Heidelberg Ion   |                    |                   |               |                |                     |                                  |
| Therapy Centre   |                    |                   |               |                |                     |                                  |
| (Germany)        |                    |                   |               |                |                     |                                  |
| Yamazaki et al. [27] | CT               | 25.5 cm³ (2–188)  | GTV–CTV margin: 5 mm | CTV–PTV margin: 3 mm | NR | No chemotherapy within 1 mo of commencing reRT |
| 2000–2010        | 57.6 (43.2–70.2) in 16 fractions/5×/wk | curative (100%) | | | | |
| (multi-institution*) | | | | | | |
| (Japan)          | | | | | | |
| Feehan et al. [28] | Heavy charged particle (helium, neon) | NR | NR | NR | 10 pts received chemotherapy before, during, or after reRT; details not specified |
| 1981–1990        | 50.25 (31.8–62.3) | curative (100%)  |               |                |                     |                                  |
| Lawrence Berkeley Laboratory (United States) | | | | | | |
| Held et al. [29] | CT                 | CTV volume 85.2 cm³ (6.3–710.5) | PTV volume 128.9 cm³ (13.3–925) | GTV–CTV margin: 2–5 mm | CTV–PTV margin: 2–3 mm | None |
| 2010–2017        | 51 (36–86)/6Gy fraction/5–6 fractions/wk | curative (100%) | | | | |
| Heidelberg Ion   |                    |                   |               |                |                     |                                  |
| Therapy Centre   |                    |                   |               |                |                     |                                  |
| (Germany)        |                    |                   |               |                |                     |                                  |
| Hayashi et al. [30]| CT            | 10.4 cm³ (0.5–89.5) | GTV–CTV margin: 0–5 mm | CTV–PTV margin: 2 mm | NR | No chemotherapy within 1 mo of commencing reRT |
| 2007–2016        | 54 (40–64)/8–16 fractions | curative (100%) | | | | |
| Hospital National Institute of Radiological Sciences (Japan) | | | | | | |
### Table 2. Extended.

| Author [citation] | Median age, y | Median F/u (mo) | Clinical outcomes | CT acute toxicities, G (%) | CT late toxicities, G (%) |
|-------------------|---------------|-----------------|-------------------|---------------------------|--------------------------|
| Hu et al. [25]    | 48            | 15.4            | 1-y OS: 98.1%     | No ≥ G2 acute toxicities  | G3 mucositis (9%)        |
| (2015–2017)       |               |                 | 1-y DSS: 98.1%    |                           | G3 brain necrosis (1%)   |
| Shanghai Proton   |               |                 | 1-y PFS: 82.2%    |                           | G3 xerostomia (1%)       |
| and Heavy Ion     |               |                 | 1-y LRFS: 86.6%   |                           |                          |
| Center (China)    |               |                 | 1-y RRFS: 97.9%   |                           |                          |
|                   |               |                 | 1-y DMFS: 96.2%   |                           |                          |
|                   |               |                 |                   |                           |                          |
| Jensen et al. [26]| 51            | 4               | OR rate: 53% 8 weeks post RT (non-chordoma/chondrosarcoma) | No ≥ G3 acute toxicities | No late toxicities reported due to short F/u |
| (2009–2010)       |               |                 | 4/5 pts chordoma/chondrosarcoma with no signs of progression |                           |                          |
| Heidelberg Ion    |               |                 |                   |                           |                          |
| Therapy Centre    |               |                 |                   |                           |                          |
| (Germany)         |               |                 |                   |                           |                          |
| Yamazaki et al. [27]| 55        | 8               | 1-y OS: 68%       | G3 nerve palsy (8%)       | G3 mucosal ulceration (8%)|
| (2000–2010)       |               |                 | 1-y LC: 67%       | G3 skin ulceration (4%)   | G4 visual disturbance (8%)|
| (multi-institution) (Japan) | | |                   | G4 soft tissue necrosis (4%) | G5 bleeding (8%) |
|                   |               |                 |                   | G5 ORN (4%)                | G5 soft tissue necrosis (4%) |
| Feehan et al. [28]| 48            | 28.1            | 3-y OS: 59%       | G2–3 brain necrosis (25%)  | G3 dysphagia (1.3%)      |
| (1981–1990)       |               |                 | 5-y OS: 31%       | G3 fistula (0.4%)          | G3 fistula (0.4%)        |
| Lawrence Berkeley |               |                 | LC: 45%           | G3 impaired hearing (0.4%) | G4 laryngeal edema (0.9%)|
| Laboratory (United States) | | |                   | G3 brain necrosis (4%) | G5 brain necrosis (4%)    |
|                   |               |                 |                   | G3 impaired hearing (4%)   | G3 optic nerve (1.6%)    |
| Held et al. [29]  | NR            | 28.5            | Median PFS: 24.2 mo | G3 optic nerve (1.6%)      | G3 fascicula (0.8%)     |
| (2010–2017)       |               |                 | Median OS: 26.1 mo |                           | G3 ORN (0.8%)            |
| Heidelberg Ion    |               |                 |                   | G4 optic nerve (1.6%)      |                           |
| Therapy Centre    |               |                 |                   | G4 brain necrosis (0.8%)   |                           |
| (Germany)         |               |                 |                   | G4 bleeding (0.8%)         |                           |
|                   |               |                 |                   |                           |                          |
| Hayashi et al. [30]| 56.5 at initial radiation | 27.1 | 2-y LC: 40.5% | G3 mucositis (8%)         | G3 dermatitis (2%)       |
| (2007–2016)       |               |                 | 2-y LRC: 33.5%    | G3-4 brain necrosis (4%)   | G5 brain necrosis (2%)   |
| Hospital National Institute of Radiological Sciences (Japan) | | | 2-y PFS: 29.4% | G3–4 optic nerve (23%) | G3 cataract (2%) |
|                   |               |                 | 2-y OS: 59.6%     | G3 trismus (2%)            | G3 dysphagia (2%)        |
|                   |               |                 |                   | G4 arterial injury (2%)    |                           |
### Table 2. Continued.

| Author [citation] | study period | institution (country) | Study type | No. pts | Primary site histology (%) | Previous RT technique (%) | Recurrent site salvage surgery before reRT (%) | median previous RT dose (range)/fractionation | median time to reRT (mo) | median No. previous RT treatments (range) |
|-------------------|--------------|-----------------------|------------|---------|----------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------|-----------------------------------------|
| Jensen et al. [31] | 2010–2013    | Heidelberg Ion Therapy Centre (Germany) | Retrospective, single institution | 52      | NR | ACC (100%) | 14 pts prior CT, rest of cases not specified | Paranasal (36%), base of skull/intracranial (21%), parotid (19%), SMG (6%), nasopharynx (4%), pterygopalatine fossa (4%), orbit (4%), other (6%) | 7 (13%) | 61 (9–620) |
| Combs et al. [32] | 1997–2008    | University Hospital of Heidelberg (Germany) | Retrospective, single institution | 28      | Skull base (64%), head and neck (18%), brain (11%), sacrum (7%) | EBRT (65%) | skull base (68%), head and neck (14%), brain (11%), sacrum (7%) | 66 Gy (20–115) | 71 (13%) | 61 (9–620) |
| Gao et al. [33]   | 2015–2017    | Shanghai Proton and Heavy Ion Center (China) | Retrospective, single institution | 141     | Nasopharynx (78%), nasal cavity/paranasal sinus (6%), oropharynx (3%), salivary glands (3%), larynx/hypopharynx (1%), other (3%) | IMRT (91%) | SBRT Gamma Knife (n = 7, 50%) | 60 Gy (24–78) | 46.7 | 1 prior course (89%) |
| Guan et al. [34]  | 2014–2018    | Shanghai Proton and Heavy Ion Center (China) | Retrospective, single institution | 14/91   | Skull base (93%), cervical spine (7%): numbers are for the entire cohort | SBRT Gamma Knife (n = 7, 50%) | SBRT Cyber Knife (n = 2, 14%) | 63.4 Gy (50–79.7) for non-SRS pts | 1 prior course only (100%) |
| Vischioni et al. [35] | 2013–2016 | National Center of Oncological Hadrontherapy (Italy) | Retrospective, single institution | 51      | Salivary gland (100%) | EBRT photon (100%) | Parotid (33%), nasal cavity (10%), nasopharynx (6%), maxillary sinus (10%), ethmoid (6%), hard palate (6%), other different sites (30%) | 60 Gy (24–78) | 40 (78%) | 6.3 y |

Abbreviations: pts, patients; RT, radiotherapy; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning target volume; OAR, organs at risk; F/u, follow-up; CT, carbon ion therapy; SCC, squamous cell carcinoma; IMRT, intensity-modulated radiation therapy; NR, not reported; IMCT, intensity-modulated carbon therapy; ENL, elective nodal irradiation; TP, docetaxel and cisplatin; GP, gemcitabine and cisplatin; CDDP, cisplatin; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival; LRFS, local recurrence–free survival; RRFS, regional recurrence–free survival; DMFS, distant metastasis–free survival; EAC, external auditory canal; ACC, adenoid cystic carcinoma; EBRT, external beam radiotherapy; PBT, proton beam therapy; max; maximum; BS, branch site; OR, XXXX; LC, local control; adeno, adenocarcinoma; 3D, 3-dimensional; ORN, osteonecrosis; SMG submandibular gland; DC, XXXX; PTB, Physikalisch-Technische Bundesanstalt; SRS, stereotactic radiosurgery; FSRT, fractionated stereotactic radiotherapy; LPFS, locoregional progression-free survival; RPFS, regional progression-free survival; DPFS, disease progression-free survival; DM, distant metastasis.

**a**Multi-institutions: Kyoto Prefectural University of Medicine; CyberKnife Center Soseikai General Hospital; Hyogo Ion Beam Medical Center; Fujimoto Hayasuzu Hospital; Japanese Red Cross Okayama Hospital; National Hospital Organization Osaka National Hospital; Osaka University Graduate School of Medicine; Miyakoigma IGRT Clinic.

---

**Gamez et al. (2021), Int J Particle Ther**

146
### Table 2. Continued. Extended.

| Author [citation] | study period | institution (country) | reRT technique (%) | Median reRT dose (range)/fractionation | Median GTV (range) | GTV–CTV margin | CTV–PTV margin | OAR doses Gy (range) | Additional systemic therapies (%) |
|-------------------|--------------|-----------------------|-------------------|----------------------------------------|-------------------|----------------|-----------------|-----------------------|----------------------------------|
| Jensen et al. [31] | 2010–2013    | Heidelberg Ion Therapy Centre (Germany) | CT alone (92%), IMRT + CT (8%) | 51 (36–74)/3 Gy/fraction/curative (100%) | CTV volume 93 cm³ (6–618): CT alone | CTV volume 334 cm³ (211–344): IMRT + CT | CTV–PTV margin: 2 mm | Max cumulative dose to spinal cord <50 Gy | Med cumulative dose to BS <60 Gy | ENI not performed, in the pts who received IMRT coverage of local regional nodal levels was allowed |
| Combs et al. [32] | 1997–2008    | University Hospital of Heidelberg (Germany) | CT (active raster scanning) alone (75%), IMRT or FSRT + CT (25%) | 51 (42–60)/3 Gy per fraction (SBT) | 45 Gy/3 Gy/fraction (HN tumors) | Curative (100%) | NR | NR | NR | No concurrent chemotherapy performed |
| Gao et al. [33]   | 2015–2017    | Shanghai Proton and Heavy Ion Center (China) | IMCT (100%) | 60 (50–69)/2–3.5 Gy/fraction | GTV–CTV margin: 3–5 mm, smaller margin allowed if close to critical OAR | CTV–PTV margin: 1–3 mm | NR | ENI not allowed | Presalvage IMCT (45%), concurrent chemotherapy not recommended except for pts participating in clinical trial (% not specified) |
| Guan et al. [34]  | 2014–2018    | Shanghai Proton and Heavy Ion Center (China) | PBT + IMCT boost (n = 6, 43%), IMCT alone (n = 8, 57%) | 50 Gy (PBT) + 15–18 Gy (IMCT boost), 57–69 Gy/19–23 fractions if IMCT alone | 37 cm³, not specifically reported for reRT pts | GTV–CTV margin: 1–3 mm | CTV–PTV margin: no > 5 mm | NR | NR | Not performed |
| Vischioni et al. [35] | 2013–2016    | National Center of Oncological Hadrontherapy (Italy) | CT (100%) | 60 Gy (45–68.8)/3–5 Gy fraction/4×/wk | 28.58 cm³ (1.75–205.54) | GTV–CTV margin: 0–5 mm | CTV–PTV margin: 2 mm | NR | NR | |
| Author [citation] | study period | Median age, y | Median F/u (mo) | Clinical outcomes | CT acute toxicities, G (%) | CT late toxicities, G (%) |
|------------------|--------------|--------------|----------------|------------------|--------------------------|--------------------------|
| Jensen et al. [31] | 2010–2013 | 54 | 14 | 1-y LC: 70% 1-y OS: 82% 1-y DC: 73% | No acute ≥ G3 toxicity G3 dysphagia (2%) G3 brain necrosis (4%) G3 ORN (6%) G4 bleeding (4%) |
| Heidelberg Ion Therapy Centre (Germany) | | | | | |
| Combs et al. [32] | 1997–2008 | <\&thinsp65 (86%) ≥ 65 (14%) | 41 | 2-y LC: 92% (SBT) 3-y LC: 64% (SBT) 2-y OS: 86% (SBT) 5-y OS: 43% (SBT) Median LPFS 24 mo (HN tumors), all HN pts death on last F/u | No ≥ G3 complications reported for skull base or head and neck tumors treated |
| University Hospital of Heidelberg (Germany) | | | | | |
| Gao et al. [33] | 2015–2017 | 49 | 14.7 | 1-y OS: 96% 1-y DSS: 96% 1-y LPFS: 85% 1-y RPFS: 98% 1-y DPFS: 96% | ≥ G3 bleeding (1%) ≥ G3 mucosal necrosis (7%) with 4 pts dying of secondary bleeding, ≥ G3 brain necrosis (1%) ≥ G3 xerostomia (1%) ≥ G3 cranial neuropathy (2%) |
| Shanghai Proton and Heavy Ion Center (China) | | | | | |
| Guan et al. [34] | 2014–2018 | 38 | 28 | At time of analysis (n = 7), 50% of reRT pts had died of uncontrolled local disease 2-y OS: 50% (reRT) | Not specifically reported for reRT pts |
| Shanghai Proton and Heavy Ion Center (China) | | | | | |
| Vischioni et al. [35] | 2013–2016 | 60 | 19 | 1-y PFS: 72% 2-y PFS: 52% 1-y OS: 90% 2-y OS: 64% At last F/u LC: 41%, and DM rate: 33% | G3 acute toxicity (4%), toxicity not clearly specified G3 late toxicity (17%), toxicity not clearly specified in all cases G3 visual deficit (6%) G3 neuropathy (2%) G3 trismus (8%) |
| National Center of Oncological Hadrontherapy (Italy) | | | | | |
the management of recurrent head and neck malignancies. All studies were retrospective in nature, and the majority (23 of 26 studies, 88%) belonged to single institutional experiences (13 of 15 studies, 87% for protons, and 9 of 10 studies, 90% for carbon ions; the only helium/neon study also involved one institution). Geographically 10 (67%) of the 15 proton series were reported by the United States, 3 (20%) from Asia, and the remaining 2 studies (13%) from Europe. With respect to carbon ion radiotherapy, all studies were implemented either in Asia 5/10 (50%) or in Europe 5/10 (50%). The study series that used charged particle therapy with Helium and Neon was carried out in the Lawrence Berkeley Laboratory in the USA. The included studies reported on patients treated between 1981–2018, with fifty percent (n=13/26) of studies (n=7/15 protons, and n=6/10 carbon ions) occurring in the last ten years, suggesting an increased availability and interest in the use of charged particle radiotherapy in the reRT setting.

Median age for the cohort of patients treated with proton therapy reRT was 57.9 years (range, 36.0–68.0 years), and 50.3 years (range, 38.0–60.0 years) for the carbon ion reRT group. These were evaluated on a per-study basis, as also for the RT doses and time intervals between RT courses reported below. The median previous RT dose was 64.5 Gy (range, 55.0–75.2 Gy, data available for 12 of the 15 studies) for the proton reRT studies, and 64.5 Gy (range, 57.6–70.0 Gy, data available for 7 of the 10 studies) for the carbon-ion reRT series. The median time interval between the initial RT and proton reRT course was 36.7 months (range, 24.7–54.0 months, data available for 9 of the 15 studies), and 46.1 months (range, 13.0–75.5 months, data available for 8 of the 10 studies) for the group of patients that subsequently received carbon ion reRT. The median proton therapy reRT dose was 64.5 Gy (RBE 1.1) (range, 50.0–75.6 Gy), (data available for 14 of the 15 studies), while the median carbon ion therapy reRT dose was 53.8 Gy (RBE 2.5–3) (range, 44.8–60.0 Gy) (data available for 9 of the 10 studies). Passive scattering/uniform scanning was the more frequently employed proton reRT technique in 11 of the 15 (73%) studies, and active scanning technique was used for carbon-ion reRT in 7 (70%) of the 10 reported series. Regarding additional systemic therapies, induction and/or concurrent chemotherapy was administered to 232 (53%) of the patients that received a course of proton reRT, and to 122 (18%) of reRT carbon ion patients. Cisplatin (CDDP) was the most commonly administered systemic agent.

With a median follow up of 23 months, reRT achieved 2-year local control (LC) rates ranging from 50% to 86% for proton reRT, and 41% to 92% for carbon ion reRT with a median follow up of 19 months. The 2-year overall survival rates for proton and carbon ion reRT ranged from 33% to 80% and 50% to 86% respectively. By head and neck subsite, the LC rates for sinonasal carcinomas ranged from 59 to 77%; nasopharyngeal carcinoma, 50% to 80%; and for salivary gland tumors, 60% to 86% with proton-beam reRT. For carbon-ion reRT, the LC rates for sinonasal carcinomas ranged from 41% to 67%; nasopharyngeal carcinoma, 45 to 85%; and 41% to 92% for salivary gland tumors. With respect to OS, the rates for sinonasal, nasopharyngeal carcinoma, and salivary gland tumors were 57% to 76%, 33% to 74%, and 57% to 80% with proton beam reRT, and 60% to 70%, 59 to 68%, and 64 to 82% with carbon-ion reRT.

In regard to dosimetric analysis, only 3 (20%) of the 15 proton reRT series, and none of the carbon ion reRT series, reported a detailed analysis of the employed constraints and delivered doses for the organs at risk. There was noted to be significant variability across series in the size of the tumor volumes treated, the margins employed for gross tumor volume (GTV) to the clinical target volume (CTV) expansion, and CTV to the planning target volume (PTV) expansion (Tables 1 and 2). In all series, elective nodal irradiation (ENI) was not routinely performed. With respect to associated treatment toxicities, the rates for acute grade 3 toxicities ranged from 1% to 35%, with dysphagia, mucositis and radiation dermatitis being the most frequent, and the rates for late grade ≥3 toxicities ranged up to 37% for protons and up to 35% for carbons, with brain necrosis, ototoxicity, visual deficits, and bleeding were most commonly reported. There was a total of 16 cases of grade 5 reported toxicities for all treated patients (n=16/1118, 1.4%) with fatal bleeding as the leading cause (Tables 1 and 2).

Discussion

Locoregional recurrences remain a common pattern of failure, morbidity and death in head and neck cancer patients [36–38]. Even with multimodality therapy, patients typically have poor oncologic outcomes, with increased severe treatment related toxicities [39–41].

Management of patients suffering from recurrent head and neck cancer is typically very challenging with no single treatment algorithm appropriate for all patients. Recurrent head and neck cancers are a heterogeneous group of patients, involving a number of different histologies and disease subsites. When evaluating a patient for reRT, a multidisciplinary evaluation that considers patient age, baseline comorbidities, performance status, histology, tumor biology, anatomic location, prior treatment constraints/toxicities, time interval since prior RT course, organ dysfunction (tracheostomy, feeding tube dependency), and

Gamez et al (2021), Int J Particle Ther
patient goals and expectations is essential to determine which interventions may be the most appropriate [42]. To our knowledge this is the first comprehensive systematic review of the current existing data on the use of charged particle reRT for the definitive management of recurrent or secondary skull base and head and neck malignancies.

Published literature on the use of photon radiotherapy reRT for recurrent or second primary skull base and head and neck cancers have shown significant variability in the reported outcomes and toxicities, depending on photon therapy modality used (3D-conformal, IMRT, brachytherapy, IORT, SBRT), delivered dose and additional therapies employed, with 2-yr LC rates ranging from 19% – 67% and 2-yr OS rates ranging from 11% – 81% and with ≥ grade 3 toxicities up to 59%, and in some series risk of grade 5 toxicity (often secondary to carotid rupture) in up to 24% [7, 39 – 41, 43 – 54]. Our analysis demonstrated 2-year local control rates in the range of 50% to 86% for proton, and 41% to 92% for carbon ion reRT. The 2-yr OS rates for proton and carbon ion reRT ranged from 33% to 80% and 50% to 86% respectively. In regards to treatment related late ≥ grade 3 toxicities this ranged between 0% to 37% overall, with only sixteen grade 5 reported toxicities of the 1118 analyzed patients for a 1.4% rate (Tables 1 and 2).

Table 3 summarizes reported clinical outcomes by reRT modality [7, 39 – 41, 43 – 54]. Although no conclusive comparisons can be drawn from these data given inherent differences in patient selection among the studies, results are suggestive that potentially more favorable LC and toxicity outcomes could be realized with charged particle therapy in properly selected patients. Of note, SBRT reRT data which do not include concurrent systemic therapy, demonstrate lowest rates of severe late toxicity likely due to smaller treatment target volumes in these studies, yet with largely similar LC compared to other photon studies. A proposition to utilize proton SBRT with concurrent immunotherapy to enhance LC, while limiting severe toxicity is currently under investigation [ClinicalTrials.gov Identifier: NCT03539198]. More advanced charged particle delivery techniques such as intensity-modulated proton beam therapy (IMPT), and intensity-modulated carbon ion therapy may further improve the therapeutic window for reirradiation. This may enable treatment of larger recurrent tumors with higher doses which would otherwise be more difficult to achieve with photon-based SBRT reRT approaches, due to greater collateral dose to organs-at-risk when treating larger treatment volumes [55].

This systematic review is not exempt from several limitations including most of the evaluated series were retrospective from single institutions, with significant variability in patient selection, recurrent disease sites, histologies, treatment technique, doses and fractionation employed, and the reported toxicities and outcomes. In addition, there were also statistical limitations and biases of the analysis due to the inherent heterogeneity of the reRT reports and lack of availability critical data within some of the reRT series, including prior RT doses, median interval times between RT courses and not having well defined study endpoints that could impact on the interpretation of the outcomes. There are no randomized data comparing outcomes with photons (IMRT, SBRT) versus charged particle reRT (protons, carbon ions). With the continuous increase in availability of centers with capability to deliver charged particle radiotherapy we can anticipate more data will emerge, and help to further elucidate the potential clinical benefits of these treatment modalities.

Efforts should continue to be made to design clinical trials that can collect robust data on the use of charged particle reRT, and would advance the management of these patients resulting in a better understanding on the selection of patient candidates for this treatment paradigm. A published patient selection RPA classification may facilitate patient stratification in future studies using charged particle reRT, to inform best study design and treatment strategies [56]. Despite the complexity in the management of these malignancies, the current accumulated information on the use of charged particle reRT for recurrent

**Table 3.** Reported results by reirradiation modality.

| Treatment [source] | 2-year LC, % | 2-year OS, % | Grade 3+ late toxicity, % |
|--------------------|--------------|--------------|--------------------------|
| Proton therapy [current study] | 50–86 | 33–80 | 0–33 |
| Carbon ion [current study] | 41–92 | 59–82 | 0–37 |
| SBRT [45–47] | 30–58 | 14–58 | 0–18 |
| IMRT [7, 48–51] | 19–67 | 12–68 | 15–48 |
| 3DCRT [39–41, 53, 54] | 20–37 | 11–81 | 21–59 |
| BT (HDR and LDR) [52] | 31–69 | 13–43 | 4–36 |

Abbreviations: LC, local control; OS, overall survival; SBRT, stereotactic body radiotherapy; IMRT, intensity-modulated radiotherapy; 3DCRT, 3-dimensional conformal radiotherapy; BT, brachytherapy; HDR, high-dose rate; LDR, low-dose rate.
Conclusions

Based on the current available data, curative intent head and neck reRT with charged particle radiotherapy is feasible and well tolerated in the majority of patients, with the potential to improve oncologic and toxicity outcomes in well-selected cases. Prospective studies of patients reporting in more depth oncologic outcomes and dosimetric treatment planning data are necessary to further validate these findings.

ADDITIONAL INFORMATION AND DECLARATIONS

CRediT: All authors: writing of the original draft, review, and editing of the manuscript; Mauricio E. Gamez and Jean-Claude M. Rwigema: study conceptualization, data curation, and formal analysis.

Conflicts of Interest: Terence T. Sio, M.D. provides strategic and scientific recommendations as a member of the Advisory Board and speaker for Novocure, Inc., which is not in any way associated with the content or disease site as presented in this manuscript. The authors have no other relevant conflicts of interest to disclose.

Funding: The authors have no funding to disclose.

Ethical approval: This review did not involve human subjects/participants and was exempt from IRB approval.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.

2. Bernier J, Domenge C, Ozsahin M, Matuszew ska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, Van Glabbeke M. Postoperative irradiation with or without concomitant chemotherapy for locoregionally advanced head and neck cancer. N Engl J Med. 2004; 350 (19): 1945–1952.

3. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Clifford Chao KS, Schultz CJ, Lee N, Fu KK. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350 (19): 1937–1944.

4. Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck. 1999; 21(7): 591–594.

5. Taussky D, Dulguerov P, Allal AS. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck. 2005; 27:182–186.

6. Spencer SA, Harris J, Wheeler RH, Mach tay M, Schultz C, Spanos W, Rotman M, Meredith R. RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2001; 51(5): 1299–1304.

7. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009; 73(2):399–409.

8. Rwigema JC, Nguyen D, Heron DE, Chen AM, Lee P, Wang PC, Vargo JA, Low DA, Saiful Huq M, Tenn S, Steinberg ML, Kupelian P, Sheng K. 4pi noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity. Int J Radiat Oncol Biol Phys. 2015; 91(2):401–409.

9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269.

10. Dionisi F, Croci S, Giacomelli I, Cianchetti M, Caldara A, Bertolin M, Vanoni V, Pertile R, Widesott L, Farace P, Schwarz M, Amichetti M. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. Acta Oncol. 2019; 58(9): 1238–1245.

Gamez et al (2021), Int J Particle Ther
11. Hayashi Y, Nakamura T, Mitsudo K, Kimura K, Yamaguchi H, Ono T, Azami Y, Takayama K, Hirose K, Yabuuchi T, Suzuki M, Hatayama Y, Kikuchi Y, Wada H, Fuwa N, Hareyama M, Tohnai I. Re-irradiation using proton beam therapy combined with weekly intra-arterial chemotheraphy for recurrent oral cancer. Asia Pac J Clin Oncol. 2017; 13(5): e394–e401.

12. McDonald MW, Zolali-Meybodi O, Lehnert SJ, Estabrook NC, Liu Y, Cohen-Gadol AA, Moore MG. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. Int J Radiat Oncol Biol Phys. 2016; 96(4):808–819.

13. Linton OR, Moore MG, Brigance JS, Summerlin DJ, McDonald MW. Proton therapy for head and neck adenoid cystic carcinoma: initial clinical outcomes. Head Neck. 2015; 37: 117–124.

14. Yu NY, Gamez ME, Hartsell WF, Tsai HK, Laramore GE, Larson GL, Simone II CB, Rossi C, Katz SR, Buras MR, Golafshar MA, Vargas CE, Patel SH. A multi-Institutional experience of proton beam therapy for sinonasal tumors. Adv Radiat Oncol. 2019; 4(4): 689–698.

15. Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer. 2020; 126: 1905–1916.

16. Ng SW, Wang H, Pollard III C, Nguyen T, Bahig H, Fuller CD, Gunn GB, Garden AS, Reddy JP, Morrison WH, Shah S, Rosenthal DI, Frank SJ, Guha-Thakurta N, Ferrarotto R, Hanna EY, Su SY, Phan J. Patient outcomes after reirradiation of small skull base tumors using stereotactic body radiotherapy, intensity modulated radiotherapy, or proton therapy. J Neurol Surg B Skull Base. 2020; 81(6): 638–644.

17. Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox JL, Mah D, Garg MK, Chang JHC, Lee NY. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016; 95(1): 386–395.

18. Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Beadle B, Ma D, Zafero ME, Hutcheson KA, Kupferman ME, William Jr WN, Frank SJ. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016; 96(1): 30–41.

19. Azami Y, Hayashi Y, Nakamura T, Kimura K, Yamaguchi H, Ono T, Takayama K, Hirose K, Yabuuchi T, Suzuki M, Hatayama Y, Hareyama M, Kikuchi Y, Fuwa N. Proton Beam Therapy for Locally Recurrent Parotid Gland Cancer. Indian J Otolarngol Head Neck Surg. 2019; 71(Suppl 1): 49–54.

20. Yamazaki, H, Demizu Y, Okimoto T, Ogita M, Himei K, Nakamura S, Suzuki G, Yoshida K, Kotsuma T, Yoshioka Y, Oh R. Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy. Strahlenther Onkol. 2017; 193: 525–533.

21. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys. 2013; 87: 1107–1114.

22. McDonald MW, Zolali-Meybodi O, Lehnert SJ, Estabrook NC, Liu Y, Cohen-Gadol AA, Moore MG. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. Int J Radiat Oncol Biol Phys. 2016; 96(4):808–819.

23. Lin R, Slater JD, Yonemoto LT, Grove RI, Teichman SL, Watt DK, Slater JM. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy – dose-volume histogram analysis. Radiology. 1999; 213: 489–494.

24. Hu J, Bao C, Gao J, Guan X, Hu W, Yang J, Hu C, Kong L, Lu JJ. Intensity-Modulated Proton and Carbon-Ion Radiation Therapy in the Management of Head and Neck Sarcomas. Cancer Med. 2019; 8(10): 4574–4586.

25. Dale JE, Molinelli S, Ciurlia E, Ciocca M, Bonora M, Vitolo V, Mirandola A, Russo S, Occhion R, Dahl O, Fossati P, et al. Risk of carotid blowout after reirradiation with particle therapy. Adv Radiat Oncol. 2017; 2(3): 465–474.

26. Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES, Munzenrider JE. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011; 79(3): 842–846.

27. Feehan PE, Castro JR, Phillips TL, Petti P, Collier M, Daftari I, Fu K. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation. Int J Radiat Oncol Biol Phys. 1992; 23: 881–884.
29. Held T, Windisch P, Akbaba S, Lang K, El Shafie R, Bernhardt D, Plinkert P, Kargus S, Rieken S, Herfarth K, Debus J, Adeberg S. Carbon ion reirradiation for recurrent head and neck cancer: a single-institutional experience. Int J Radiat Oncol Biol Phys. 2019; 105(4): 803–811.

30. Hayashi K, Koto M, Ikawa H, Hagiwara Y, Tsuji H, Ogawa K, Kamada T. Feasibility of re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. Radiother Oncol. 2019; 136: 148–153.

31. Jensen AD, Poulakis M, Nikoghosyan AV, Chaudhri N, Uhl M, Munter MW, Herfarth KK, Debus J. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother Oncol. 2015; 114: 182–188.

32. Combs SE, Kalbe A, Nikoghosyan A, Ackermann B, Jakel O, Haberer T, Debus J. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol. 2011; 98: 63–67.

33. Gao J, Hu J, Guan X, Yang J, Hu W, Kong L, Lu JJ. Salvage carbon-ion radiation therapy for locoregionally recurrent head and neck malignancies. Scientific Reports. 2019; 9: 4259.

34. Guan X, Gao J, Hu J, Hu W, Yang J, Qiu X, Hu C, Kong L, Lu JJ. The preliminary results of proton and carbon ion therapy for chordoma and chondrosarcoma of the skull base and cervical spine. Radiation Oncology. 2019; 14: 206.

35. Vischioni B, Dhanireddy B, Severo C, Bonora M, Ronchi S, Vitolo V, Fiore MR, D’Ippolito E, Petrucci R, Barcellini A, Ciurlia E, Iannalfi A, Hasegawa A, Molinelli S, Miranda A, Valvo F, Orecchia R. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. Radiother Oncol. 2020; 145: 172–177.

36. Emami B, Bignardi M, Spector GJ. Reirradiation of recurrent head and neck cancers. Laryngoscope. 1987; 97(1): 85–88.

37. Slootweg PJ, Bolle CW, Koole R, Hordijk GJ. Cause of death in squamous cell carcinoma of the head and neck. An autopsy study on 31 patients. J Cranio-maxillofac Surg. 1992; 20(5): 225–227.

38. Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol. 2002; 116(4): 269–271.

39. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice – daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25(30): 4800–4805.

40. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R, Ang KK. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 30(3): 281–288.

41. Janot F, De Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Gery B, Julieron M, Castaing M, Bardet E, Gregoire V, Bourhis J. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008; 26: 5518–5523.

42. Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys 2011; 81(5): 1211–1219.

43. Scala LM, Hu K, Urken ML, Jacobson AS, Persky MS, Tran TN, Smith ML, Schantz S, Harrison LB. Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer. Head Neck. 2013; 35(4): 485–492.

44. Wald P, Grecula J, Walston S, Wei L, Bhatt A, Martin D, Bonomi M, Rocco J, Old M, Teknos T, Blakaj D. Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer. Head Neck. 2019; 41(7): 2148–2153.

45. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S. Stereotactic body radiation therapy for primary recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2009; 74(4): 1047–1053.

46. Vargo JA, Ward MC, Caudell JC, Riaz N, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Higgins KA, Hassanadeh C, Beittler JJ, Reddy CA, Marcom S, Boggis DH, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA, Ferris RL, Heron DE. A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2018; 100(3): 595–605.

47. Lim CM, Clump DA, Heron DE, Ferris RL. Stereotactic body radiotherapy (SBRT) for primary and recurrent head and neck tumors. Oral Oncol. 2013; 49(5): 401–406.
48. Lee J, Shin IS, Kim WC, Yoon WS, Koom WS, Rim CH. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: meta-analysis and systematic review. Head Neck. 2020; 42(9): 2473–2485.

49. Lee N, Chan K, Bekelman, Zhung J, Mechalakos J, Narayana A, Wolden SL, Benkatraman ES, Pfister D, Kraus D, Shah J, Zelefsky MJ. Salvage Re-Irradiation for Recurrent Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2007; 68(3): 731–740.

50. Sher DJ, Haddad RI, Norris Jr CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010; 116(20): 4761–4768.

51. Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, Gunn GB, Fuller CD, Beadle B, Frank SJ, William Jr WN, Kies M, El-Naggar AK, Weber R, Rosenthal DI, Phan J. Reirradiation of head and neck cancers with intensity-modulated radiation therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016; 95(4): 1117–1131.

52. Rudzianskas V, Inciura A, Juozaityte E, Rudzianskiene M, Kubilius R, Vaitkus S, Kaseta M, Adliene D. Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. Acta Otorhinolaryngol Ital. 2012; 32(5): 297–303.

53. Dawson LA, Myers LL, Bradford CR, Chepeha DB, Hogikyan ND, Teknos TN, Terrell JE, Wolf GT, Eisbruch A. Conformal re-irradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50(2): 377–385.

54. De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A, Mamelle G, Janot F, Julieron M, Leridant AM, Marandas P, Armand JP, Schwaab G, Loboinski B, Eschwege F. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998; 16(11): 3556–3562.

55. Rwigema JCM, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. J Clin Oncol. 2011; 34(4): 372–379.

56. Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow K, Zakem SJ, Dault J, Awan MJ, Vargo JA, Heron DE, Higgins KA, Beitler JJ, Marcom S, boggs DH, Hassanzadeh C, Reddy CA, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA. Refining patient selection for reirradiation of head and neck squamous cell carcinoma in the IMRT era: a multi-institution cohort study by THE MIRI collaborative. Int J Radiat Oncol Biol Phys. 2018; 100(3): 586–594.